Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice

Annals of Surgical Oncology

Volumn 13, Issue 9, 2006, Pages 1252-1258

  Viehl, Carsten T ^a,b   Moore, Todd T ^a   Liyanage, Udaya K ^a   Frey, Daniel M ^a,b   Ehlers, Jesmin P ^a   Eberlein, Timothy J ^a,c   Goedegebuure, Peter S ^a,c   Linehan, David C ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c USA   (United States)

Author keywords

Animal study; Cancer vaccine; Pancreas cancer; Regulatory T cells; Tumor immunity

Indexed keywords

ANTIBODY; CANCER VACCINE; CD4 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; TUMOR CELL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HOST; IMMUNE RESPONSE; LYMPHOCYTE; MOUSE; NONHUMAN; PANCREAS CANCER; PREVALENCE; SPLEEN CELL; TUMOR CELL; TUMOR IMMUNITY;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERFERON TYPE II; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; RECEPTORS, INTERLEUKIN-2; SPLEEN; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY;

EID: 33748957938     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9015-y     Document Type: Article

References (33)

1. Takahashi T, Kuniyasu Y, Toda M, et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998; 10:1969-80.
2. Shevach EM, McHugh RS, Thornton AM, Piccirillo C, Natarajan K, Margulies DH. Control of autoimmunity by regulatory T cells. Adv Exp Med Biol 2001; 490:21-32.
3. Kojima A, Tanaka-Kojima Y, Sakakura T, Nishizuka Y. Spontaneous development of autoimmune thyroiditis in neonatally thymectomized mice. Lab Invest 1976; 34:550-7.
4. Stumbles PA, Penhale WJ. IDDM in rats induced by thymectomy and irradiation. Diabetes 1993; 42:571-8.
5. Kontani K, Taguchi O, Takahashi T. Involvement of the H+/K(+)-ATPase alpha subunit as a major antigenic protein in autoimmune gastritis induced by neonatal thymectomy in mice. Clin Exp Immunol 1992; 89:63-7.
6. Kojima A, Sakakura T, Tanaka Y, Nishizuka Y. Sterility in neonatally thymectomized female mice: its nature and prevention by the injection of spleen cells. Biol Reprod 1973; 8:358-61.
7. Malmstrom V, Shipton D, Singh B, et al. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J Immunol 2001; 166:6972-81.
8. Thornton AM, Shevach EM. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J Immunol 2000; 164:183-90.
9. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001; 167:1137-40.
10. Azuma T, Takahashi T, Kunisato A, Kitamura T, Hirai H. Human CD4+CD25+ regulatory T cells suppress NKT cell functions. Cancer Res 2003; 63:4516-20.
11. Powrie F, Carlino J, Leach MW, Mauze S, Coffman RL. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells. J Exp Med 1996; 183:2669-74.
12. Seddon B, Mason D. Regulatory T cells in the control of autoimmunity: the essential role of transforming growth factor beta and interleukin 4 in the prevention of autoimmune thyroiditis in rats by peripheral CD4(+)CD45RC- cells and CD4(+)CD8(-) thymocytes. J Exp Med 1999; 189:279-88.
13. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001; 193:1303-10.
14. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299:1057-61.
15. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 2003; 9:606-12.
16. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61:4766-72.
17. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD4 + CD25 + regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer 2003; 98:1089-99.
18. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9.
19. Awwad M, North RJ. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells. Cancer Res 1989; 49:1649-54.
20. North RJ, Dye ES. Ly 1 +2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma. Immunology 1985; 54:47-56.
21. Rakhmilevich AL, North RJ, Dye ES. Presence of CD4+ T suppressor cells in mice rendered unresponsive to tumor antigens by intravenous injection of irradiated tumor cells. Int J Cancer 1993; 55:338-43.
22. Awwad M, North RJ. Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4 + suppressor T cells from a host generating predominantly Lyt-2 + T cell-mediated immunity. J Exp Med 1988; 168:2193-206.
23. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 1999; 59:3128-33.
24. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25 + CD4 + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163:5211-8.
25. Sutmuller RP, van Duivenvoorde LM, van Elsas A, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194:823-32.
26. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002; 169:2756-61.
27. + regulatory T-cells in cancer. Immunol Res 2005; 32:155-68.
28. Janik P, Briand P, Hartmann NR. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res 1975; 35:3698-704.
29. Liyanage UK, Goedegebuure PS, Moore TT, et al. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother 2006; 29:416-24.
30. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90:3539-43.
31. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004; 200:771-82.
32. Stephens GL, McHugh RS, Whitters MJ, et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4 + CD25 + T cells. J Immunol 2004; 173:5008-20.
33. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003; 100:8372-7.